Innovation Theater Lunch: A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence (non-accredited/non-approved for CECH)

This luncheon will provide a review of the clinical evidence supporting an expanded portfolio of placental and umbilical-derived allografts products, and the technology behind them. Two Randomized Controlled Trials will be discussed by expert clinicians to provide insight into the evidence supporting perinatal allografts. Scientific data behind the portfolio will also be presented to highlight the processing technologies that drive clinical outcomes.

Topics:
The New BioStem Technologies - Who are we? The technology behind BioStem's broad, innovative suite of placental & umbilical-derived birth tissue products Recently published DFU RCT results Incorporating birth tissue into your practice Q & A
Sponsored by BioStem Technologies.